Grifols Dirección

Dirección controles de criterios 2/4

El CEO de Grifols' es Nacho Abia Buenache, nombrado en Apr 2024, tiene una permanencia de menos de un año. posee directamente un 0.014% de las acciones de la empresa, con un valor de €696.63K. La antigüedad media del equipo directivo y de la junta directiva es de 6.3 años y 8.4 años, respectivamente.

Información clave

Nacho Abia Buenache

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	less than a year
Participación del CEO	0.01%
Permanencia media de la dirección	6.3yrs
Promedio de permanencia en la Junta Directiva	8.5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Nacho Abia Buenache (55 yo)

less than a year

Permanencia

Mr. Jose Ignacio Abia Buenache, also known as Nacho, serves as Chief Executive Officer of Grifols, S.A. from April 1, 2024 and has been its Director since February 26, 2024. Mr. Abia Buenache had been Chie...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.6m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	sin datos	0.014% € 765.1k
Alfredo Guerra	CFO & VP	17.3yrs	sin datos	sin datos
Lluis Gomez	Senior Vice President of Strategy & COO Office	no data	sin datos	sin datos
Nuria Lapeña	VP of Corporate Treasury	no data	sin datos	sin datos
David Bell	Chief Corporate Development	21.3yrs	sin datos	0.0029% € 165.1k
Maria Teresa-Rioné Llano	Chief Communications Officer	6.3yrs	sin datos	0.00078% € 43.7k
Camille Alpi	Chief Human Resources & Talent Officer	less than a year	sin datos	sin datos
Vicente Blanquer Torre	Chief Quality Officer	31.3yrs	sin datos	0.0066% € 368.8k
Sergio Adell	President of Commercial Tech Support	5.3yrs	sin datos	sin datos
Víctor Grifols Deu	Executive Director	no data	€1.04m	0.0022% € 120.3k
Miguel Montblanch	President of Commercial Operations Support	12.3yrs	sin datos	sin datos

6.3yrs

Permanencia media

58.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 0RDU es experimentado (9.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Thomas Glanzmann	Executive Chairman	18.1yrs	€1.90m	0.029% € 1.6m
Jose Ignacio Abia Buenache	CEO & Director	less than a year	sin datos	0.014% € 765.1k
Víctor Grifols Deu	Executive Director	8yrs	€1.04m	0.0022% € 120.3k
Juan Twose Roura	Member of the Advisory Committee	9.3yrs	€380.00k	sin datos
Raimon Grifols Roura	Vice-Chairman	9yrs	€1.04m	0.0060% € 338.6k
Tomas Daga Gelabert	Independent External Director	24.1yrs	sin datos	0.045% € 2.5m
Inigo Mardones	Independent Director	9yrs	€150.00k	sin datos
Carina Szpilka Lázaro	Lead Independent Director	9yrs	€150.00k	0.00022% € 12.3k
James Costos	Independent Director	3.6yrs	€138.00k	sin datos
Albert Coma-Cros	Proprietary Director	less than a year	sin datos	0.0097% € 544.0k
Enriqueta Font	Independent Director	5yrs	€125.00k	sin datos
Montserrat Abellana	Independent Director	1.9yrs	€63.00k	sin datos

8.5yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 0RDU se considera experimentada (8.4 años de antigüedad promedio).

Grifols Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Insufficient new directors

Recent updates

Grifols, S.A. to Report Q1, 2024 Results on May 14, 2024

Now 20% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 41%

Full year 2023 earnings released

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols, S.A. Provides Earnings Guidance for the Year 2024

Grifols Announces Positive Topline Phase 3 Fibrinogen Clinical Trial Results

Grifols, S.A. Announces CEO Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. Announces Board Changes

Grifols, S.A. to Report Fiscal Year 2023 Results on Feb 29, 2024

Grifols Launches New Solution to Facilitate Pre-Transfusion Compatibility Testing in Multiple Myeloma Patients

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-In-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Third quarter 2023 earnings released

Grifols Appoints Miguel Louzan as Chief Digital Information Officer

New major risk - Financial position

Second quarter 2023 earnings released

Grifols Achieves Positive Topline Results from Phase 4 Study of Xembify® (Immune Globulin Subcutaneous Human-Klhw) Evaluating Biweekly Dosing Option for Patients

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Grifols Reportedly in Talks to Sell Raas Stake to China Resources

New major risk - Financial position

Grifols, S.A. to Report Q3, 2023 Results on Nov 02, 2023

Grifols, S.A., Annual General Meeting, Jun 15, 2023

Grifols Launches Alphaid™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic Copd

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings released

Now 20% undervalued

Grifols, S.A. to Report Fiscal Year 2022 Results on Feb 28, 2023

Now 22% undervalued

Now 22% undervalued after recent price drop

Insufficient new directors

Grifols, S.A. to Report Q3, 2022 Results on Nov 08, 2022

Grifols Receives FDA Clearance for AlphaID(TM) At Home, the First Free Service for U.S. Consumers to Determine Their Risk for Alpha-1

Insufficient new directors

Grifols Announces Management Changes

Second quarter 2022 earnings released

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Now 20% undervalued after recent price drop

Now 20% undervalued

Grifols, S.A. to Report First Half, 2022 Results on Jul 28, 2022

Now 20% undervalued

Now 23% undervalued

Grifols, S.A., Annual General Meeting, Jun 09, 2022

Insufficient new directors

Grifols, S.A. (BME:GRF) completed the acquisition of a 45.48% stake in Biotest Aktiengesellschaft (XTRA : BIO3) from Tiancheng International Investment Limited.

Full year 2021 earnings: Revenues miss analyst expectations

Grifols, S.A. (BME:GRF) acquired Grifols Escrow Issuer, S.A.U. for $0.06 million.

Investor sentiment improved over the past week

Now 22% undervalued after recent price drop

Second quarter 2021 earnings released

Independent External Director Ramon Riera Roca has left the company

Grifols to Provide Korean Red Cross with Procleix Panther for Blood Screening, Extending Donor Testing Leadership in Asia

Grifols, S.A. Declares Ordinary Dividend for the Fiscal Year Ended December 31, 2020, Payable on June 7, 2021

Grifols Takes Another Step in the Fight Against Alzheimer's, Partners with Ace to Open First Ambar® Center in Barcelona

First quarter 2021 earnings released: EPS €0.19 (vs €0.27 in 1Q 2020)

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Grifols Launches Patient Point-Of-Care System for Monitoring Infliximab in Europe

Grifols, S.A. (BME:GRF) acquired remaining 56% stake in GigaGen, Inc. for $80 million

Grifols, S.A. (BME:GRF) acquired 25 U.S. Based Plasma Donation Centers of BPL Plasma, Inc for $370 million.

Full year 2020 earnings released: EPS €0.90 (vs €0.91 in FY 2019)

Revenue misses expectations

New 90-day low: €20.77

New 90-day low: €23.08

Grifols, S.A.(BME:GRF.P) dropped from S&P Global BMI Index

Grifols Begins Clinical Trial of A New Treatment That Would Provide Immediate Immunity Against Covid-19

CEO

Permanencia